OBJECTIVES: To determine the effect of statins on cognitive decline in healthy elderly adults. DESIGN: Longitudinal. SETTING: National Institute of Aging network of Alzheimer's Disease Centers. PARTICIPANTS: Research volunteers with normal cognition at baseline evaluated an average 4.1 times over 3.4 years (1,244 statin users, 2,363 nonusers) and with mild cognitive impairment (MCI) at baseline evaluated an average 3.9 times over 2.8 years (763 users, 917 nonusers). MEASUREMENTS: Cognitive performance was assessed according to 10 neuropsychological indices and the Clinical Dementia Rating Sum of Boxes (CDR-SOB). Repeated-measures analyses adjusted for age, sex, education, comorbidities, and family history of dementia were conducted. RESULTS: Of participants with normal cognition at baseline, statin users performed significantly better across all visits in attention (Trails A) and had significantly slower annual worsening in CDR-SOB scores (P = .006) and slower worsening in Mini-Mental State Examination scores than nonusers (which was not significant after adjusting for multiple comparisons, P = .05). For participants with MCI, statin users performed significantly better across all visits on attention measures (Trail-Making Test Part A), verbal skills (Category Fluency), and executive functioning (Trail-Making Test Part B, Digit Symbol, and Digits Backward), but there were no differences in cognitive decline between users and nonusers. CONCLUSION: Elderly adults with normal cognition at baseline who used statins had a slower rate of annual worsening in CDR-SOB than nonusers.
OBJECTIVES: To determine the effect of statins on cognitive decline in healthy elderly adults. DESIGN: Longitudinal. SETTING: National Institute of Aging network of Alzheimer's Disease Centers. PARTICIPANTS: Research volunteers with normal cognition at baseline evaluated an average 4.1 times over 3.4 years (1,244 statin users, 2,363 nonusers) and with mild cognitive impairment (MCI) at baseline evaluated an average 3.9 times over 2.8 years (763 users, 917 nonusers). MEASUREMENTS: Cognitive performance was assessed according to 10 neuropsychological indices and the Clinical Dementia Rating Sum of Boxes (CDR-SOB). Repeated-measures analyses adjusted for age, sex, education, comorbidities, and family history of dementia were conducted. RESULTS: Of participants with normal cognition at baseline, statin users performed significantly better across all visits in attention (Trails A) and had significantly slower annual worsening in CDR-SOB scores (P = .006) and slower worsening in Mini-Mental State Examination scores than nonusers (which was not significant after adjusting for multiple comparisons, P = .05). For participants with MCI, statin users performed significantly better across all visits on attention measures (Trail-Making Test Part A), verbal skills (Category Fluency), and executive functioning (Trail-Making Test Part B, Digit Symbol, and Digits Backward), but there were no differences in cognitive decline between users and nonusers. CONCLUSION: Elderly adults with normal cognition at baseline who used statins had a slower rate of annual worsening in CDR-SOB than nonusers.
Authors: Ge Li; Jane B Shofer; Isaac C Rhew; Walter A Kukull; Elaine R Peskind; Wayne McCormick; James D Bowen; Gerard D Schellenberg; Paul K Crane; John C S Breitner; Eric B Larson Journal: J Am Geriatr Soc Date: 2010-06-01 Impact factor: 5.562
Authors: D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Donald J Connor; Lisa M Sparks; Carolyn Liebsack Journal: Curr Alzheimer Res Date: 2008-08 Impact factor: 3.498
Authors: Peter P Zandi; D Larry Sparks; Ara S Khachaturian; Joann Tschanz; Maria Norton; Martin Steinberg; Kathleen A Welsh-Bohmer; John C S Breitner Journal: Arch Gen Psychiatry Date: 2005-02
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Stella Trompet; Peter van Vliet; Anton J M de Craen; Jelle Jolles; Brendan M Buckley; Michael B Murphy; Ian Ford; Peter W Macfarlane; Naveed Sattar; Chris J Packard; David J Stott; Jim Shepherd; Eduard L E M Bollen; Gerard J Blauw; J Wouter Jukema; Rudi G J Westendorp Journal: J Neurol Date: 2009-08-04 Impact factor: 4.849
Authors: Neelesh K Nadkarni; Subashan Perera; Joseph T Hanlon; Oscar Lopez; Anne B Newman; Howard Aizenstein; Marshall Elam; Tamara B Harris; Stephen Kritchevsky; Kristine Yaffe; Caterina Rosano Journal: Alzheimers Dement Date: 2015-01-12 Impact factor: 21.566
Authors: Ellen C Caniglia; L Paloma Rojas-Saunero; Saima Hilal; Silvan Licher; Roger Logan; Bruno Stricker; M Arfan Ikram; Sonja A Swanson Journal: Neurology Date: 2020-08-04 Impact factor: 9.910
Authors: Sonal Singh; Susan Zieman; Alan S Go; Stephen P Fortmann; Nanette K Wenger; Jerome L Fleg; Barbara Radziszewska; Neil J Stone; Sophia Zoungas; Jerry H Gurwitz Journal: J Am Geriatr Soc Date: 2018-10-02 Impact factor: 5.562